Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$107.00 USD
+12.14 (12.80%)
Updated May 2, 2024 04:00 PM ET
After-Market: $106.90 -0.10 (-0.09%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BPMC 107.00 +12.14(12.80%)
Will BPMC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPMC
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
Other News for BPMC
Wells Fargo Remains a Buy on Blueprint Medicines (BPMC)
Blueprint Medicines Reaches Analyst Target Price
Sell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth Factors
Blueprint Medicines price target raised by $11 at JMP Securities, here's why
Blueprint Medicines price target raised by $11 at Citi, here's why